TNFSF10 and carcinoma: Human renal (Caki and ACHN), prostate (DU145), cervical (HeLa), and breast (MDA-MB231 and SKBR3) carcinoma cells showed dose-dependent increase in apoptosis upon treatment with TRAIL and pepstatin A (Pep A; a Cat D inhibitor) (Fig. 2A).